{"text": "In a prenatal / postnatal study , pregnant rats received ticagrelor at doses of 10 to 180 mg / kg / day during late gestation and lactation .", "label": "", "metadata": {}, "score": "30.336403"}
{"text": "The safety and effectiveness of ticagrelor in pediatric patients have not been established .Geriatric Use .The relative risk of bleeding was similar in both treatment and age groups .", "label": "", "metadata": {}, "score": "32.64464"}
{"text": "The effects of age , gender , ethnicity , renal impairment and mild hepatic impairment on the pharmacokinetics of ticagrelor are presented in Figure 4 .", "label": "", "metadata": {}, "score": "33.494186"}
{"text": "The effects of age , gender , ethnicity , renal impairment and mild hepatic impairment on the pharmacokinetics of ticagrelor are presented in Figure 5 .", "label": "", "metadata": {}, "score": "34.02232"}
{"text": "Despite the need to treat such results cautiously , there appears to be good reason to restrict aspirin maintenance dosage accompanying ticagrelor to 100 mg .", "label": "", "metadata": {}, "score": "34.756588"}
{"text": "Patients can be transitioned from clopidogrel to BRILINTA without interruption of antiplatelet effect [ see DOSAGE AND ADMINISTRATION ] .Pharmacokinetics .Ticagrelor demonstrates dose proportional pharmacokinetics , which are similar in patients and healthy volunteers .", "label": "", "metadata": {}, "score": "35.496483"}
{"text": "Patients can be transitioned from clopidogrel to ticagrelor without interruption of antiplatelet effect [ see dosage and Administration ( 2 ) .Pharmacokinetics .Ticagrelor demonstrates dose proportional pharmacokinetics , which are similar in patients and healthy volunteers .", "label": "", "metadata": {}, "score": "35.638996"}
{"text": "There are no adequate and well - controlled studies of ticagrelor use in pregnant women .In animal studies , ticagrelor caused structural abnormalities at maternal doses about 5 to 7 times the maximum recommended human dose ( MRHD ) based on body surface area .", "label": "", "metadata": {}, "score": "39.88518"}
{"text": "In reproductive toxicology studies , pregnant rats received ticagrelor during organogenesis at doses from 20 to 300 mg / kg / day .The lowest dose was approximately the same as the MRHD of 90 mg twice daily for a 60 kg human on a mg / m2 basis .", "label": "", "metadata": {}, "score": "41.81741"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable .Safety , Tolerability , Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers .", "label": "", "metadata": {}, "score": "42.866684"}
{"text": "ticagrelor can be administered with or without food .A patient who misses a dose of ticagrelor should take one 90 mg tablet ( their next dose ) at its scheduled time .", "label": "", "metadata": {}, "score": "42.922638"}
{"text": "See Pharmacology .Other Concomitant Therapy .Ticagrelor can be administered with unfractionated or low - molecular - weight heparin , GPIIb / IIIa inhibitors , proton pump inhibitors , beta - blockers , angiotensin converting enzyme inhibitors , and angiotensin receptor blockers .", "label": "", "metadata": {}, "score": "43.756134"}
{"text": "Ticagrelor and AR - C124910XX were shown to have no inhibitory effect on human CYP1A2 , CYP2C19 , and CYP2E1 activity .For specific in vivo effects on the pharmacokinetics of simvastatin , atorvastatin , ethinyl estradiol , levonorgesterol , tolbutamide , digoxin and cyclosporine , see Figure 6 .", "label": "", "metadata": {}, "score": "43.80149"}
{"text": "Ticagrelor , like other antiplatelet agents , can cause significant , sometimes fatal bleeding .Do not use ticagrelor in patients with active pathological bleeding or a history of intracranial hemorrhage .", "label": "", "metadata": {}, "score": "43.92404"}
{"text": "Figure 4 - Impact of intrinsic factors on the pharmacokinetics of ticagrelor .Habitual smoking increased population mean clearance of ticagrelor by approximately 22 % when compared to non - smokers .", "label": "", "metadata": {}, "score": "44.10414"}
{"text": "Absorption of ticagrelor occurs with a median tmax of 1.5 h ( range 1.0 - 4.0 ) .The formation of the major circulating metabolite AR - C124910XX ( active ) from ticagrelor occurs with a median tmax of 2.5 h ( range 1.5 - 5.0 ) .", "label": "", "metadata": {}, "score": "45.547943"}
{"text": "Most of the analyses show effects consistent with the overall results , but there are two exceptions : a finding of heterogeneity by region and a strong influence of the maintenance dose of aspirin .", "label": "", "metadata": {}, "score": "47.46463"}
{"text": "BRILINTA can be taken with or without food .Absorption of ticagrelor occurs with a median tmax of 1.5 h ( range 1.0- 4.0 ) .", "label": "", "metadata": {}, "score": "47.511257"}
{"text": "No data exist with Ticagrelor regarding a hemostatic benefit of platelet transfusions .Drug Discontinuation .In PLATO , the rate of study drug discontinuation attributed to adverse reactions was 7.4 % for Ticagrelor and 5.4 % for Clopidogrel .", "label": "", "metadata": {}, "score": "48.071144"}
{"text": "In vitro metabolism studies demonstrate that ticagrelor and its major active metabolite are weak inhibitors of CYP3A4 , potential activators of CYP3A5 and inhibitors of the P - gp transporter .", "label": "", "metadata": {}, "score": "48.14893"}
{"text": "The mean absolute bioavailability of ticagrelor is about 36 % ( range 30%-42 % ) .Ingestion of a high - fat meal had no effect on ticagrelor Cmax , but resulted in a 21 % increase in AUC .", "label": "", "metadata": {}, "score": "48.757774"}
{"text": "Immunocompromised Patients .There is no FDA guidance one the use of Ticagrelor in patients who are immunocompromised .Administration and Monitoring .Administration .[ [ Orall .", "label": "", "metadata": {}, "score": "48.923573"}
{"text": "The purpose of this study is to evaluate the safety profile , tolerability , pharmacokinetics , and pharmacodynamics following 14-day multiple oral doses BMS-708163 in healthy young male Japanese and healthy elderly male and female Japanese subjects .", "label": "", "metadata": {}, "score": "49.051853"}
{"text": "Serum uric acid levels increased approximately 0.6 mg / dL from baseline on Ticagrelor and approximately 0.2 mg / dL on Clopidogrel in PLATO .The difference disappeared within 30 days of discontinuing treatment .", "label": "", "metadata": {}, "score": "49.281273"}
{"text": "How Supplied .Brilinta ( ticagrelor ) 90 mg is supplied as a round , biconvex , yellow , film - coated tablet marked with a \" 90 \" above \" T \" on one side .", "label": "", "metadata": {}, "score": "49.320732"}
{"text": "Patients undergoing PCI could receive an additional 300 mg of clopidogrel at investigator discretion .All subjects randomized to Brilinta received a loading dose of 180 mg followed by a maintenance dose of 90 mg twice daily .", "label": "", "metadata": {}, "score": "51.07821"}
{"text": "Stopping ticagrelor increases the risk of subsequent cardiovascular events .The following adverse reactions are also discussed elsewhere in the labeling : Warnings .Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in the clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice .", "label": "", "metadata": {}, "score": "52.01329"}
{"text": "In the absence of a placebo control , whether these are drug related can not be determined in most cases , except where they are more common on Ticagrelor or clearly related to the drug 's pharmacologic effect ( dyspnea ) .", "label": "", "metadata": {}, "score": "52.16681"}
{"text": "The offset of IPA was examined after 6 weeks on ticagrelor 90 mg twice daily or clopidogrel 75 mg daily , again in response to 20 \u03bcM", "label": "", "metadata": {}, "score": "52.318077"}
{"text": "The offset of IPA was examined after 6 weeks on ticagrelor 90 mg twice daily or clopidogrel 75 mg daily , again in response to 20 \u03bcM", "label": "", "metadata": {}, "score": "52.318077"}
{"text": "The offset of IPA was examined after 6 weeks on ticagrelor 90 mg twice daily or clopidogrel 75 mg daily , again in response to 20 \u03bcM", "label": "", "metadata": {}, "score": "52.318077"}
{"text": "In the US 57 % of patients received doses above 100 mg and 54 % received doses above 300 mg .Figure 10 shows overall results by median aspirin dose .", "label": "", "metadata": {}, "score": "53.13289"}
{"text": "Ingestion of a high - fat meal had no effect on ticagrelor Cmax , but resulted in a 21 % increase in AUC .The Cmax of its major metabolite was decreased by 22 % with no change in AUC .", "label": "", "metadata": {}, "score": "53.297894"}
{"text": "Stopping ticagrelor increases the risk of subsequent cardiovascular events .WARNING : ( A )BLEEDING RISK , and ( B ) ASPIRIN DOSE AND ticagrelor EFFECTIVENESS .", "label": "", "metadata": {}, "score": "53.645065"}
{"text": "Patients can be transitioned from clopidogrel to ticagrelor without interruption of antiplatelet effect [ see dosage and Administration ( 2 ) .Structure .Ticagrelor cyclopentyltriazolopyrimidine , inhibitor of platelet activation and aggregation mediated by the P2Y12 ADP - receptor .", "label": "", "metadata": {}, "score": "53.73264"}
{"text": "As shown in Figure 4 , mean maximum IPA following the last dose of ticagrelor was 88 % and 62 % for clopidogrel .After 5 days , IPA in the ticagrelor group was similar to IPA in the placebo group .", "label": "", "metadata": {}, "score": "53.88775"}
{"text": "As shown in Figure 3 , mean maximum IPA following the last dose of ticagrelor was 88 % and 62 % for clopidogrel .After 5 days , IPA in the ticagrelor group was similar to IPA in the placebo group .", "label": "", "metadata": {}, "score": "54.094025"}
{"text": "As shown in Figure 3 , mean maximum IPA following the last dose of ticagrelor was 88 % and 62 % for clopidogrel .After 5 days , IPA in the ticagrelor group was similar to IPA in the placebo group .", "label": "", "metadata": {}, "score": "54.094025"}
{"text": "After the initial loading dose of aspirin ( usually 325 mg ) , use ticagrelor with a daily maintenance dose of aspirin of 75 - 100 mg .", "label": "", "metadata": {}, "score": "54.115456"}
{"text": "Effects of Other Drugs on Ticagrelor .CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite .The effects of other drugs on the pharmacokinetics of ticagrelor are presented in Figure 5 as change relative to ticagrelor given alone ( test / reference ) .", "label": "", "metadata": {}, "score": "55.068577"}
{"text": "Figure 3 : Mean inhibition of platelet aggregation ( \u00b1SE ) following single oral doses of placebo , 180 mg ticagrelor or 600 mg clopidogrel .", "label": "", "metadata": {}, "score": "55.636986"}
{"text": "Brilinta .CLINICAL PHARMACOLOGY .Mechanism Of Action .Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP - receptor to prevent signal transduction and platelet activation .", "label": "", "metadata": {}, "score": "55.6514"}
{"text": "Ticagrelor and its active metabolite are approximately equipotent .The inhibition of platelet aggregation ( IPA ) by ticagrelor and clopidogrel was compared in a 6 week study examining both acute and chronic platelet inhibition effects in response to 20 \u03bcM", "label": "", "metadata": {}, "score": "55.711723"}
{"text": "Figure 5 : Impact of intrinsic factors on the pharmacokinetics of ticagrelor .Effects of Other Drugs on BRILINTA .CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite .", "label": "", "metadata": {}, "score": "55.781082"}
{"text": "Strong CYP3A inhibitors ( e.g. , ketoconazole , itraconazole , and clarithromycin ) substantially increase ticagrelor exposure .Moderate CYP3A inhibitors have lesser effects ( e.g. , diltiazem ) .", "label": "", "metadata": {}, "score": "56.171158"}
{"text": "The primary route of elimination for the major metabolite of ticagrelor is most likely to be biliary secretion .The mean t1/2 is approximately 7 hours for ticagrelor and 9 hours for the active metabolite .", "label": "", "metadata": {}, "score": "56.26415"}
{"text": "The onset of IPA was evaluated on Day 1 of the study following loading doses of 180 mg ticagrelor or 600 mg clopidogrel .As shown in Figure 2 , IPA was higher in the ticagrelor group at all time points .", "label": "", "metadata": {}, "score": "56.836613"}
{"text": "The onset of IPA was evaluated on Day 1 of the study following loading doses of 180 mg ticagrelor or 600 mg clopidogrel .As shown in Figure 2 , IPA was higher in the ticagrelor group at all time points .", "label": "", "metadata": {}, "score": "56.836613"}
{"text": "In the mouse and dog , maximum plasma concentration of radioactivity was observed in less than 1 h after an oral [ 14C]prasugrel dose .Most of the administered prasugrel dose was recovered in the faeces of rats and dogs ( 72 % and 52 - 73 % , respectively ) , and in mice urine ( 54 % ) .", "label": "", "metadata": {}, "score": "56.882736"}
{"text": "The onset of IPA was evaluated on Day 1 of the study following loading doses of 180 mg ticagrelor or 600 mg clopidogrel .As shown in Figure 3 , IPA was higher in the ticagrelor group at all time points .", "label": "", "metadata": {}, "score": "56.96875"}
{"text": "The primary route of elimination for the major metabolite of ticagrelor is most likely to be biliary secretion .The mean t\u00bd is approximately 7 hours for ticagrelor and 9 hours for the active metabolite .", "label": "", "metadata": {}, "score": "56.999424"}
{"text": "Higher doses do not have an established benefit in the ACS setting , and there is a strong suggestion that use of such doses reduces the effectiveness of Brilinta .", "label": "", "metadata": {}, "score": "57.18914"}
{"text": "Although the efficacy profiles of the two regimens were similar , the lower dose had lower risks of bleeding and dyspnea .Table 8 shows the results for the 60 mg plus aspirin regimen vs. aspirin alone .", "label": "", "metadata": {}, "score": "58.07466"}
{"text": "This study indicates that fentanyl buccal tablet has predictable pharmacokinetics following multiple - dose administration ... .Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics .", "label": "", "metadata": {}, "score": "58.554535"}
{"text": "Cangrelor , a molecule very similar to ticagrelor , is currently being evaluated against clopidogrel .Considering the key balance of ischemic protection and bleeding risk , this paper discusses the background to the development of prasugrel , ticagrelor , and cangrelor and aims to characterise their risk - benefit profile and possible implementation in daily practice .", "label": "", "metadata": {}, "score": "58.610992"}
{"text": "A daily maintenance dose of aspirin 75 - 100 mg was recommended , but higher maintenance doses of aspirin were allowed according to local judgment .", "label": "", "metadata": {}, "score": "58.907005"}
{"text": "A daily maintenance dose of aspirin 75 - 100 mg was recommended , but higher maintenance doses of aspirin were allowed according to local judgment .", "label": "", "metadata": {}, "score": "58.907005"}
{"text": "Figure 2 - Mean inhibition of platelet aggregation ( \u00b1SE ) following single oral doses of placebo , 180 mg ticagrelor or 600 mg clopidogrel .", "label": "", "metadata": {}, "score": "59.816402"}
{"text": "Figure 2 - Mean inhibition of platelet aggregation ( \u00b1SE ) following single oral doses of placebo , 180 mg ticagrelor or 600 mg clopidogrel .", "label": "", "metadata": {}, "score": "59.816402"}
{"text": "The aims of this study are to assess the safety , tolerance , and pharmacokinetics of single oral doses of GSK1322888 and to identify a well - tolerated and safe dose that will accelerate gastric emptying of a 13C stable isotope - labeled test meal in healthy volunteers .", "label": "", "metadata": {}, "score": "59.94038"}
{"text": "Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis : a pilot study .Mona Darwish Clinical Pharmacology , Cephalon , Inc , Frazer , Pennsylvania 19355 , USA Clin Drug Investig 27:605 - 11 .", "label": "", "metadata": {}, "score": "60.156143"}
{"text": "They significantly reduce platelet activity and are therefore clinically beneficial in settings where platelet activation is a key pathophysiological feature , particularly myocardial infarction .Ticlopidine , the first of the class introduced to clinical practice , was soon challenged and almost completely replaced by clopidogrel for its better tolerability .", "label": "", "metadata": {}, "score": "60.495735"}
{"text": "There is limited information about Labor and Delivery of Ticagrelor tablet in patients .Nursing Mothers .There is limited information about Nursing Mothers of Ticagrelor tablet in patients .", "label": "", "metadata": {}, "score": "60.661983"}
{"text": "The results indicate that administration of low - dose dextroamphetamine in this dosing regimen does not alter the steady - state pharmacokinetics of modafinil .The combination has a similar tolerability profile as modafinil alone ... .", "label": "", "metadata": {}, "score": "60.841476"}
{"text": "Relatively minor effects such as delays in pinna unfolding and eye opening occurred at doses of 10 and 60 mg / kg ( approximately one - half and 3.2 times the MRHD on a mg / m2 basis ) .", "label": "", "metadata": {}, "score": "61.233776"}
{"text": "Both the 60 mg and 90 mg regimens of BRILINTA in combination with aspirin were superior to aspirin alone in reducing the incidence of CV death , MI or stroke .", "label": "", "metadata": {}, "score": "61.99004"}
{"text": "A Prospective , Randomized , Double - Blind , Placebo - Controlled , Dose - Escalation , Phase 1 Study to Evaluate the Pharmacokinetics , Safety , and Tolerability of Single Doses of Mipomersen Administered Subcutaneously to Japanese Healthy Subjects .", "label": "", "metadata": {}, "score": "62.42285"}
{"text": "In a Holter substudy of about 3000 patients in PLATO , more patients had ventricular pauses with Ticagrelor ( 6.0 % ) than with Clopidogrel ( 3.5 % ) in the acute phase ; rates were 2.2 % and 1.6 % respectively after 1 month .", "label": "", "metadata": {}, "score": "62.534256"}
{"text": "Because many drugs are excreted in human milk , and because of the potential for serious adverse reactions in nursing infants from ticagrelor , a decision should be made whether to discontinue nursing or to discontinue drug , taking into account the importance of the drug to the mother .", "label": "", "metadata": {}, "score": "62.79776"}
{"text": "Other Name : NNC 90 - 1170 .Drug : placebo .Single dose administered subcutaneously at four different dose levels : 2.5 , 5.0 , 10.0 and 15.0 mcg / kg .", "label": "", "metadata": {}, "score": "62.869156"}
{"text": "Distribution .Metabolism .CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite .Ticagrelor and its major active metabolite are weak P - glycoprotein substrates and inhibitors .", "label": "", "metadata": {}, "score": "62.89031"}
{"text": "Distribution .Metabolism .CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite .Ticagrelor and its major active metabolite are weak P - glycoprotein substrates and inhibitors .", "label": "", "metadata": {}, "score": "62.89031"}
{"text": "The chemical structure of ticagrelor is : .Ticagrelor is a crystalline powder with an aqueous solubility of approximately 10 \u03bcg / mL at room temperature .", "label": "", "metadata": {}, "score": "63.11146"}
{"text": "Moderate CYP3A inhibitors have lesser effects ( e.g. , diltiazem ) .CYP3A inducers ( e.g. , rifampin ) substantially reduce ticagrelor blood levels .P - gp inhibitors ( e.g. cyclosporine ) increase ticagrelor exposure .", "label": "", "metadata": {}, "score": "63.1262"}
{"text": "For specific in vivo effects on the pharmacokinetics of simvastatin , atorvastatin , ethinyl estradiol , levonorgesterol , tolbutamide , digoxin and cyclosporine , see Figure 7 .", "label": "", "metadata": {}, "score": "63.656036"}
{"text": "Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2 , 3A4 and 2C19 in healthy subjects .Mona Darwish Clinical Pharmacology , Cephalon Inc , Frazer , PA 19355 , USA Clin Pharmacokinet 47:61 - 74 .", "label": "", "metadata": {}, "score": "63.715534"}
{"text": "P - gp inhibitors ( e.g. , cyclosporine ) increase ticagrelor exposure .Figure 6 : Effect of co - administered drugs on the pharmacokinetics of ticagrelor .", "label": "", "metadata": {}, "score": "63.96982"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01407406 This Phase 1 study is being conducted to evaluate 3 increasing subcutaneous ( SC ) doses ( 50 , mg , 100 mg or 200 mg ) of mipomersen in Japanese healthy volunteers .", "label": "", "metadata": {}, "score": "64.4087"}
{"text": "pharmacokinetics of GSK1322888 following single , oral doses Time Frame : 48 h post dose Safety Issue : No .Adverse Events following single oral doses of GSK1322888 Time Frame : 1 week post dose Safety Issue : Yes .", "label": "", "metadata": {}, "score": "64.43779"}
{"text": "Single - dose and steady - state pharmacokinetics of fentanyl buccal tablet in healthy volunteers .Mona Darwish Clinical Pharmacology , Cephalon , Inc , Frazer , Pennsylvania , USA J Clin Pharmacol 47:56 - 63 .", "label": "", "metadata": {}, "score": "64.54152"}
{"text": "PLATO patients were predominantly male ( 72 % ) and Caucasian ( 92 % ) .Median exposure to study drug was 277 days .About half of the patients received pre - study clopidogrel and about 99 % of the patients received aspirin at some time during PLATO .", "label": "", "metadata": {}, "score": "64.59206"}
{"text": "The percentages of those patients who bled are shown in Table 2 .Rates were very high but similar for Ticagrelor and Clopidogrel .Although the platelet inhibition effect of Ticagrelor has a faster offset than Clopidogrel in in vitro tests and Ticagrelor is a reversibly binding P2Y12 inhibitor , PLATO did not show an advantage of Ticagrelor compared to Clopidogrel for CABG -related bleeding .", "label": "", "metadata": {}, "score": "64.606895"}
{"text": "All patients randomized to BRILINTA received a loading dose of 180 mg followed by a maintenance dose of 90 mg twice daily .Patients in the clopidogrel arm were treated with an initial loading dose of clopidogrel 300 mg , if clopidogrel therapy had not already been given .", "label": "", "metadata": {}, "score": "65.00728"}
{"text": "History of any significant drug allergy .Prior exposure to BMS-708163 .Exposure to any investigational drug or placebo within 4 weeks of study drug administration .", "label": "", "metadata": {}, "score": "65.15587"}
{"text": "Condition ICMJE .Diabetes .Diabetes Mellitus , Type 2 .Intervention ICMJE .Drug : liraglutide .Single dose administered subcutaneously at four different dose levels : 2.5 , 5.0 , 10.0 and 15.0 mcg / kg .", "label": "", "metadata": {}, "score": "65.24417"}
{"text": "Ticagrelor is metabolized by the liver and impaired hepatic function can increase risks for bleeding and other adverse events .Hence , ticagrelor is contraindicated for use in patients with severe hepatic impairment and its use should be considered carefully in patients with moderate hepatic impairment .", "label": "", "metadata": {}, "score": "65.43089"}
{"text": "As shown in Table 1 , Ticagrelor was associated with a somewhat greater risk of non-CABG bleeding than was Clopidogrel .No baseline demographic factor altered the relative risk of bleeding with Ticagrelor compared to Clopidogrel .", "label": "", "metadata": {}, "score": "66.45595"}
{"text": "A Single Centre , Randomised , Placebo - controlled , Four - way Cross Over Study to Assess the Safety , Tolerability , Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK573719 and GW642444 as Monotherapies and Concurrently in Healthy Japanese Subjects .", "label": "", "metadata": {}, "score": "66.46457"}
{"text": "Even if a metabolite represents a high proportion of the dose in humans and a low proportion in animals , absolute abundances in animals frequently exceed that in humans because the doses used in animal toxicology studies are much greater than therapeutic doses in humans .", "label": "", "metadata": {}, "score": "66.52125"}
{"text": "Development of these two inhaled drugs as a combination therapy is also planned and would have potential for improved efficacy and patient benefit as they both work through different receptor pathways and the combined bronchodilatory effect might be additive .", "label": "", "metadata": {}, "score": "66.57559"}
{"text": "Subjects , healthy volunteers , will receive a single dose of GSK573719 ( 500ug ) , GW642444 ( 50ug ) , GSK573719 ( 500ug)+GW642444 ( 50ug ) administered concurrently , or placebo at each of the four treatment periods .", "label": "", "metadata": {}, "score": "66.60257"}
{"text": "A positive pre - study drug / alcohol screen . -HIV positive - History of regular alcohol consumption within 6 months of the study - Exposure to more than four new chemical entities within 12 months prior to the first dosing day .", "label": "", "metadata": {}, "score": "67.0829"}
{"text": "Excretion .The primary route of ticagrelor elimination is hepatic metabolism .When radiolabeled ticagrelor is administered , the mean recovery of radioactivity is approximately 84 % ( 58 % in feces , 26 % in urine ) .", "label": "", "metadata": {}, "score": "67.114426"}
{"text": "Excretion .The primary route of ticagrelor elimination is hepatic metabolism .When radiolabeled ticagrelor is administered , the mean recovery of radioactivity is approximately 84 % ( 58 % in feces , 26 % in urine ) .", "label": "", "metadata": {}, "score": "67.114426"}
{"text": "Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers .Philmore Robertson Department of Drug Disposition , Cephalon , Inc , West Chester , PA 19380 , USA Clin Pharmacol Ther 71:46 - 56 .", "label": "", "metadata": {}, "score": "67.15272"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT01299298 The disposition and metabolism of prasugrel , a thienopyridine prodrug and a potent inhibitor of platelet aggregation in vivo , were investigated in mice , rats , and dogs .", "label": "", "metadata": {}, "score": "67.806"}
{"text": "Patients who had already been treated with clopidogrel could be enrolled and randomized to either study treatment .Patients could be included whether there was intent to manage the ACS medically or invasively , but patient randomization was not stratified by this intent .", "label": "", "metadata": {}, "score": "68.32244"}
{"text": "The subject has a known allergy or hypersensitivity to ipratropium bromide , tiotropium , atropine and any of its derivatives .Any adverse reaction including immediate or delayed hypersensitivity to any \u03b22 agonist or sympathomimetic drug .", "label": "", "metadata": {}, "score": "68.39823"}
{"text": "Patients were predominantly male ( 76 % ) Caucasian ( 87 % ) with a mean age 65 years , and 99.8 % of patients received prior Aspirin therapy .", "label": "", "metadata": {}, "score": "68.507195"}
{"text": "BLEEDING RISK , and ( B ) ASPIRIN DOSE AND Brilinta EFFECTIVENESS .See full prescribing information for complete boxed warning .Condition Name : .", "label": "", "metadata": {}, "score": "68.5639"}
{"text": "Mona Darwish Cephalon Inc , 41 Moores Road , Frazer , PA 19355 , USA J Clin Pharmacol 47:343 - 50 .The rate and extent of fentanyl absorption were greater following administration of FBT compared to OTFC .", "label": "", "metadata": {}, "score": "69.5812"}
{"text": "Most of the characteristics shown are baseline characteristics , but some reflect post - randomization determinations ( e.g. , aspirin maintenance dose , use of PCI ) .", "label": "", "metadata": {}, "score": "69.69139"}
{"text": "Study Arm ( s ) .Experimental : NNC 90 - 1170 .Intervention : Drug : liraglutide .Placebo Comparator : Placebo .Intervention : Drug : placebo .", "label": "", "metadata": {}, "score": "69.705666"}
{"text": "This trial is conducted in Japan .The aim of this trial is to assess the safety and tolerability of NNC 90 - 1170 ( liraglutide ) in healthy Japanese male subjects .", "label": "", "metadata": {}, "score": "70.067245"}
{"text": "The fentanyl buccal tablet ( FBT ) is designed to enhance the rate and extent of fentanyl absorption through the buccal mucosa ... .Pharmacokinetic properties of fentanyl effervescent buccal tablets : a phase I , open - label , crossover study of single - dose 100 , 200 , 400 , and 800 microg in healthy adult volunteers .", "label": "", "metadata": {}, "score": "70.214714"}
{"text": "Treatment with any nonprescription medicinal products ( including vitamin / mineral / herbal containing preparations but excluding acetaminophen ) within the 7 days prior to study treatment .", "label": "", "metadata": {}, "score": "70.24506"}
{"text": "Most of the characteristics shown are baseline characteristics , but some reflect post - randomization determinations ( e.g. , final diagnosis , aspirin maintenance dose , use of PCI ) .", "label": "", "metadata": {}, "score": "70.25143"}
{"text": "Median exposure to study drug was 277 days .About half of the patients received pre - study clopidogrel and about 99 % of the patients received aspirin at some time during PLATO .", "label": "", "metadata": {}, "score": "70.42178"}
{"text": "Dyspnea led to study drug discontinuation in 0.9 % of Ticagrelor and 0.1 % of Clopidogrel patients .Common Adverse Events .A variety of non - hemorrhagic adverse events occurred in PLATO at rates of 3 % or more .", "label": "", "metadata": {}, "score": "70.42481"}
{"text": "When possible , discontinue ticagrelor at least 5 days prior to any surgery .Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography , percutaneous coronary intervention ( PCI ) , CABG , or other surgery .", "label": "", "metadata": {}, "score": "70.64855"}
{"text": "The PLATO protocol left the choice of aspirin maintenance dose up to the investigator and use patterns were different in US sites from sites outside of the US .", "label": "", "metadata": {}, "score": "70.86681"}
{"text": "Study Design : This is a single - dose , Randomized , Double - Blind , parallel - group study to evaluate the PK , safety , and tolerability of BIIB023 administered intravenously ( IV ) to adult Chinese , Japanese , and Caucasian healthy volunteers .", "label": "", "metadata": {}, "score": "70.907776"}
{"text": "Male .Ages .20 Years to 45 Years .Accepts Healthy Volunteers .Yes .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects GW642444 is a potent and selective long - acting beta2 agonist ; GSK573719 is a long - acting , inhaled , muscarinic receptor antagonist ( or anticholinergic ) bronchodilator .", "label": "", "metadata": {}, "score": "71.24602"}
{"text": "Official Title ICMJE .Placebo - Controlled , Ascending Multiple - Dose Study to Evaluate the Safety , Tolerability , Pharmacokinetics , and Pharmacodynamics of BMS-708163 in Healthy Male Japanese Subjects and a Comparison to Healthy Elderly Japanese Subjects .", "label": "", "metadata": {}, "score": "71.32995"}
{"text": "Toxicol .In the present review , this framework is expanded to include a fourth tenet : considerations for the duration of exposure .Basic concepts of pharmacology are utilized to rationalize the relationship between exposure ( to parent drug or metabolite ) and various effects ranging from desired therapeutic effects through to severe toxicities .", "label": "", "metadata": {}, "score": "72.573105"}
{"text": "A Single - Dose , Randomized , Double - Blind , Parallel - Group , Phase 1 Study to Evaluate the Pharmacokinetics , Safety , and Tolerability of BIIB023 in Chinese , Japanese , and Caucasian Adult Healthy Volunteers .", "label": "", "metadata": {}, "score": "72.66495"}
{"text": "Alcohol intake within 48 hours prior to the screening .Hepatitis B surface antigen , Hepatitis C antibodies or HIV ( human immunodeficiency virus ) antibodies positive .", "label": "", "metadata": {}, "score": "73.199844"}
{"text": "While this clinical experience has not identified differences in responses between the elderly and younger patients , greater sensitivity of some older individuals can not be ruled out .", "label": "", "metadata": {}, "score": "73.83076"}
{"text": "Subjects will receive four possible treatments as single inhaled doses , receiving the two monotherapies separately , the monotherapies concurrently , and placebo .Blood samples for PK analysis will be taken at regular intervals after dosing .", "label": "", "metadata": {}, "score": "73.97355"}
{"text": "Philmore Robertson Department of Drug Disposition , Cephalon , Inc , West Chester , Pennsylvania 19380 , USA J Clin Pharmacol 42:205 - 14 .However , limitations arising from investigation of single doses of warfarin preclude global conclusions about the potential for more subtle interactions after chronic warfarin administration ... .", "label": "", "metadata": {}, "score": "74.09781"}
{"text": "Subjects will be enrolled into 1 of 3 treatment cohorts ( Cohorts A , B , and C ) in a dose - escalation design .", "label": "", "metadata": {}, "score": "74.62741"}
{"text": "A wide range of demographic , concurrent baseline medications , and other treatment differences were examined for their influence on outcome .Some of these are shown in Figure 9 .", "label": "", "metadata": {}, "score": "74.89606"}
{"text": "Serum Creatinine : .The increases typically did not progress with ongoing treatment and often decreased with continued therapy .Evidence of reversibility upon discontinuation was observed even in those with the greatest on treatment increases .", "label": "", "metadata": {}, "score": "75.02025"}
{"text": "The main circulating thiol - containing metabolite in the three animal species is the pharmacologically active metabolite , R-138727 .The thiol - containing metabolites are further metabolized by S - methylation and conjugation with cysteine .", "label": "", "metadata": {}, "score": "75.20166"}
{"text": "History of significant allergy or hypersensitivity .Known or suspected allergy to trial product or related products .History of drug or alcohol abuse .Smoking 10 cigarettes or more , or the equivalent , per day and is unwilling to refrain from smoking during 3 days prior to dosing and during the confinement period .", "label": "", "metadata": {}, "score": "75.49293"}
{"text": "Clinical pharmacokinetic profile of modafinil .Philmore Robertson Department of Drug Safety and Disposition , Cephalon , Inc , West Chester , Pennsylvania , USA Clin Pharmacokinet 42:123 - 37 .", "label": "", "metadata": {}, "score": "75.669945"}
{"text": "Mutagenesis .Ticagrelor did not demonstrate genotoxicity when tested in the Ames bacterial mutagenicity test , mouse lymphoma assay and the rat micronucleus test .The active O - demethylated metabolite did not demonstrate genotoxicity in the Ames assay and mouse lymphoma assay .", "label": "", "metadata": {}, "score": "75.70845"}
{"text": "GSK573719 is a long - acting , inhaled , muscarinic receptor antagonist or anticholinergic bronchodilator .GW642444 is a potent and selective long - acting beta-2 agonist .", "label": "", "metadata": {}, "score": "75.87032"}
{"text": "Surgery within 3 months prior to Day -1 or any surgical procedure planned during the course of the study .Previous exposure to BIIB023 .Treatment with another investigational drug , device , or approved therapy for investigational use within 30 days prior to Day -1 , or 7 half lives of the investigational product , whichever is longer .", "label": "", "metadata": {}, "score": "75.99894"}
{"text": "An analysis of recently published human ADME studies shows that the number of drug metabolites considered to be important for MIST can be excessively high if a simple percentage - of - parent - drug criterion is used without consideration of the aforementioned four tenets .", "label": "", "metadata": {}, "score": "76.37061"}
{"text": "Gender .There is no FDA guidance on the use of Ticagrelor with respect to specific gender populations .Race .There is no FDA guidance on the use of Ticagrelor with respect to specific racial populations .", "label": "", "metadata": {}, "score": "76.89278"}
{"text": "Gender .Both .Ages .20 Years and older .Accepts Healthy Volunteers .Yes .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Rationale for the Study : Phase 1 pharmacokinetic ( PK ) data is needed in Chinese and Japanese populations to support future clinical development of BIIB023 in China and Japan .", "label": "", "metadata": {}, "score": "76.915565"}
{"text": "Ajay Madan XenoTech , LLC , 16825 West 116th Street , Lenexa , KS 66219 , USA Drug Metab Dispos 31:421 - 31 .Steady - state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers .", "label": "", "metadata": {}, "score": "77.86093"}
{"text": "Clinical Studies .Patients were treated for at least 6 months and for up to 12 months .Study endpoints were obtained until the study was complete , even if drug was discontinued .", "label": "", "metadata": {}, "score": "78.031876"}
{"text": "Pharmacodynamics .The inhibition of platelet aggregation ( IPA ) by ticagrelor and clopidogrel was compared in a 6 week study examining both acute and chronic platelet inhibition effects in response to 20 \u03bcM", "label": "", "metadata": {}, "score": "78.22191"}
{"text": "Pharmacodynamics .The inhibition of platelet aggregation ( IPA ) by ticagrelor and clopidogrel was compared in a 6 week study examining both acute and chronic platelet inhibition effects in response to 20 \u03bcM", "label": "", "metadata": {}, "score": "78.22191"}
{"text": "The 95 % confidence limits that are shown do not take into account how many comparisons were made , nor do they reflect the effect of a particular factor after adjustment for all other factors .", "label": "", "metadata": {}, "score": "78.36966"}
{"text": "The 95 % confidence limits that are shown do not take into account how many comparisons were made , nor do they reflect the effect of a particular factor after adjustment for all other factors .", "label": "", "metadata": {}, "score": "78.36966"}
{"text": "The fentanyl effervescent buccal tablet ( FEBT ) is designed to enhance the rate and extent of the absorption of fentanyl , an opioid , through the buccal mucosa ... .", "label": "", "metadata": {}, "score": "78.57959"}
{"text": "This criterion must be followed from the time of the first dose of study medication until completion of the follow - up visit .No clinically active and relevant abnormality on 12-lead ECG or 24h Holter ECG at screening .", "label": "", "metadata": {}, "score": "78.81699"}
{"text": "WikiDoc does not promote any medication or off - label use of drugs .Please read our full disclaimer here .Black Box Warning .FDA Package Insert for Ticagrelor contains no information regarding Black Box Warning .", "label": "", "metadata": {}, "score": "79.21254"}
{"text": "A Randomised , Double - blind , Single - centre , Placebo - controlled , Ascending Single s.c .Dose , Sequential Group Study to Assess the Safety , Tolerability , Pharmacokinetics and Pharmacodynamics of NNC 90 - 1170 in Healthy Japanese Male Subjects .", "label": "", "metadata": {}, "score": "79.26815"}
{"text": "Patients with previous intracranial hemorrhage , gastrointestinal bleeding within the past 6 months , or with known bleeding diathesis or coagulation disorder were excluded .Patients taking anticoagulants were excluded from participating and patients who developed an indication for anticoagulation during the trial were discontinued from study drug .", "label": "", "metadata": {}, "score": "79.39284"}
{"text": "E T Hellriegel Department of Drug Disposition , Cephalon , Inc , West Chester , Pennsylvania 19380 , USA J Clin Pharmacol 41:895 - 904 .", "label": "", "metadata": {}, "score": "80.77721"}
{"text": "Surgically sterile , abstinent or subject or partner compliant with acceptable contraceptive during and 24 weeks after the last study drug dose .Exclusion Criteria : .", "label": "", "metadata": {}, "score": "80.78589"}
{"text": "History of sensitivity to any of the study medications , or components thereof or a history of drug or other allergy that , in the opinion of the investigator or GSK Medical Monitor , contraindicates their participation .", "label": "", "metadata": {}, "score": "81.61278"}
{"text": "Previous exposure to oligonucleotide - based drug therapy .Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "81.95116"}
{"text": "Last reviewed on RxList : 9/18/2015This monograph has been modified to include the generic and brand name in many instances .This study is the First Time In Human study for the motilin receptor agonist , GSK1322888 .", "label": "", "metadata": {}, "score": "82.086334"}
{"text": "Number of patients with Serious Adverse Events as a measure of safety and tolerability [ Time Frame : Participants will be followed for the duration of a study ; an expected 71 days ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "82.23305"}
{"text": "Other sex - hormonal adverse reactions , including sex organ malignancies , did not differ between the two treatment groups in PLATO .Lab abnormalities .", "label": "", "metadata": {}, "score": "82.704056"}
{"text": "Use of any other drugs , including over - the - counter medications and herbal preparations , within 2 weeks prior to study drug administration .", "label": "", "metadata": {}, "score": "83.315765"}
{"text": "Because these reactions are reported voluntarily from a population of an unknown size , it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure .", "label": "", "metadata": {}, "score": "83.50778"}
{"text": "The detection of drugs with a legitimate medical use would not necessarily be an exclusion to study participation .The detection of alcohol would not be an exclusion at screening but would need to be negative pre - dose and during the study .", "label": "", "metadata": {}, "score": "83.75029"}
{"text": "It is notable , however , that aspirin dose predicts outcome in both regions with a similar pattern , and that the pattern is similar for the two major components of the primary endpoint , CV death and non - fatal MI .", "label": "", "metadata": {}, "score": "83.819855"}
{"text": "Arms .Cohort 2 GSK1322888 ( 20 mg , 40 mg , 80 mg , and dose to be determined ; 6 subjects ) and Placebot ( 2 subjects ) .", "label": "", "metadata": {}, "score": "85.389984"}
{"text": "The consistency of the differences in both the CV mortality and non - fatal MI components , however , supports the possibility that the finding is reliable .", "label": "", "metadata": {}, "score": "85.444916"}
{"text": "The consistency of the differences in both the CV mortality and non - fatal MI components , however , supports the possibility that the finding is reliable .", "label": "", "metadata": {}, "score": "85.444916"}
{"text": "History of blood donation or blood transfusion within 4 weeks prior to the study treatment .Intolerance to oral medication or venous access .Smoking more than 10 cigarettes per day .", "label": "", "metadata": {}, "score": "85.64993"}
{"text": "The curves separate by 30 days [ relative risk reduction ( RRR ) 12 % ] and continue to diverge throughout the 12 month treatment period ( RRR 16 % ) .", "label": "", "metadata": {}, "score": "85.662186"}
{"text": "Mona Darwish Clinical Pharmacology , Cephalon Inc , Frazer , PA 19355 , USA Clin Drug Investig 28:1- 7 .e. above a molar tooth between the upper gum and cheek ) and sublingual ( i.e. placed under the tongue ) placement in order to provide an alternative option to patients ... .", "label": "", "metadata": {}, "score": "86.03429"}
{"text": "The Caucasian group is included to allow comparison of PK data from different groups using data from the same study under the same controlled conditions .", "label": "", "metadata": {}, "score": "86.80179"}
{"text": "Under Australian guidelines , one standard unit defined as 10 g of ethanol , is equivalent to 250ml of full - strength beer , 470 ml of light - strength beer , 100 ml of wine and 30ml of spirits .", "label": "", "metadata": {}, "score": "87.685265"}
{"text": "Drug : Placebo .Not Provided .Recruitment Status ICMJE .Completed .Enrollment ICMJE .Completion Date .July 2009 .Primary Completion Date .", "label": "", "metadata": {}, "score": "88.459045"}
{"text": "The results were similar for drug - eluting and bare metal stents .The Kaplan - Meier curve ( Figure 7 ) shows time to first occurrence of the primary composite endpoint of CV death , non - fatal MI or non - fatal stroke in the overall study .", "label": "", "metadata": {}, "score": "88.55623"}
{"text": "( with the exception of basal cell carcinoma that has been completely excised prior to study ) .History of clinically important severe allergic or anaphylactic reactions .", "label": "", "metadata": {}, "score": "88.582565"}
{"text": "In this study , their effects are investigated following individual and concurrent administration .Healthy as determined by a responsible and experienced physician , based on a medical evaluation including medical history , physical examination , laboratory tests and cardiac monitoring .", "label": "", "metadata": {}, "score": "89.62528"}
{"text": "No dosage adjustment is needed in patients with renal impairment .Patients receiving dialysis have not been studied [ see Clinical Pharmacology .Hepatic Impairment .", "label": "", "metadata": {}, "score": "89.7888"}
{"text": "Blood pressure in supine position at the screening , after resting for 5 min , outside the ranges 90 - 150 mmHg systolic or 40 - 90 mmHg diastolic .", "label": "", "metadata": {}, "score": "89.81154"}
{"text": "Do not use ticagrelor in patients with active pathological bleeding or a history of intracranial hemorrhage .Do not start ticagrelor in patients planned to undergo urgent coronary artery bypass graft surgery ( CABG ) .", "label": "", "metadata": {}, "score": "90.0497"}
{"text": "Interventions : .Drug : BMS-708163 .Drug : Placebo .Experimental : BMS-708163 - Panel 4 .( age 65 or above ) .Interventions : .", "label": "", "metadata": {}, "score": "90.51401"}
{"text": "Figure 10 : CV death , MI , stroke by maintenance aspirin dose in the US and outside the US ( PLATO ) .Like any unplanned subset analysis , especially one where the characteristic is not a true baseline characteristic ( but may be determined by usual investigator practice ) , the above analyses must be treated with caution .", "label": "", "metadata": {}, "score": "90.642204"}
{"text": "- Regular use of tobacco- or nicotine - containing products within 6 months prior to screening .- Consumption of red wine , seville oranges , grapefruit or grapefruit juice and/or pummelos , exotic citrus fruits , grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication .", "label": "", "metadata": {}, "score": "91.799194"}
{"text": "The curves separate by 30 days ( RRR 12 % ) and continue to diverge throughout the 12 month treatment period ( RRR 16 % ) .", "label": "", "metadata": {}, "score": "92.16287"}
{"text": "Eligibility Criteria ICMJE .Inclusion Criteria : .Healthy subjects as determined by no clinically significant deviation from normal in medical history , physical examination , ECGs , and clinical laboratory determinations .", "label": "", "metadata": {}, "score": "92.66092"}
{"text": "Must be willing to abstain from using tobacco and tobacco - containing products during the in - clinic period .Must be willing to limit alcohol intake to no more than 2 units per day throughout the duration of the study ( with some stricter exceptions at various timepoints ) .", "label": "", "metadata": {}, "score": "92.78892"}
{"text": "Table 5 shows results by region and dose .Table 5 - PLATO : CV Death , MI , Stroke by maintenance aspirin dose in the US and outside the US .", "label": "", "metadata": {}, "score": "92.83884"}
{"text": "On enrolment into the study , subjects will be assigned to one of four treatment sequences which are based on a Williams design in accordance with the randomization schedule generated by GSK prior to study start .", "label": "", "metadata": {}, "score": "92.992874"}
{"text": "Many of these are shown in Figure 8 .Such analyses must be interpreted cautiously , as differences can reflect the play of chance among a large number of analyses .", "label": "", "metadata": {}, "score": "93.05837"}
{"text": "In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil .P Robertson Department of Drug Safety and Disposition , Cephalon , Inc , West Chester , Pennsylvania , USA Drug Metab Dispos 28:664 - 71 .", "label": "", "metadata": {}, "score": "93.14184"}
{"text": "The results in the subsets based on final diagnosis ( STEMI , NSTEMI and unstable angina ) are also presented in Figure 8 .Results in the rest of the world compared to effects in North America ( US and Canada ) show a smaller effect in North America , numerically inferior to the control and driven by the US subset .", "label": "", "metadata": {}, "score": "93.20747"}
{"text": "A mean heart rate outside the range 40 - 90 bpm at screening .The subject has a positive pre - study drug / alcohol screen .", "label": "", "metadata": {}, "score": "93.58741"}
{"text": "Regional Differences .Results in the rest of the world compared to effects in North America ( US and Canada ) show a smaller effect in North America , numerically inferior to the control and driven by the US subset .", "label": "", "metadata": {}, "score": "93.66928"}
{"text": "Any significant acute or chronic medical illness .Any current or recent ? medical history of gastrointestinal disease that may affect evaluation of study treatment .", "label": "", "metadata": {}, "score": "94.176865"}
{"text": "John L Marshall Georgetown University Medical Center Lombardi Cancer Center , Washington , DC 20007 , USA Invest New Drugs 23:31 - 7 .The objectives were to determine the maximum tolerated dose ( MTD ) , dose - limiting toxicities , and pharmacokinetic profile of this orally administered agent ... .", "label": "", "metadata": {}, "score": "94.512634"}
{"text": "Serious infection ( e.g. , pneumonia , septicemia ) within the 2 months prior to Screening .History of drug or alcohol abuse ( as defined by the Investigator ) within 6 months prior to screening , and/or a positive urine drug screen ( without a medically indicated rationale ) or positive alcohol breath test at Screening or on Day -1 .", "label": "", "metadata": {}, "score": "95.26275"}
{"text": "Evidence of acute or ongoing chronic inflammatory condition or infection .History of rash , impetigo , or drug allergies .Alcohol and/or drug abuse .", "label": "", "metadata": {}, "score": "95.28824"}
{"text": "Requires medical intervention to stop or treat bleeding ( e.g. , epistaxis requiring visit to medical facility for packing ) .Minimal bleed .All others ( e.g. , bruising , bleeding gums , oozing from injection sites , etc . ) not requiring intervention or treatment .", "label": "", "metadata": {}, "score": "95.474106"}
{"text": "Pharmacogenetics .Clinical Studies .Acute Coronary Syndromes And Secondary Prevention After Myocardial Infarction .PLATO .The study 's primary endpoint was the composite of first occurrence of cardiovascular death , non - fatal MI ( excluding silent MI ) , or non - fatal stroke .", "label": "", "metadata": {}, "score": "95.56961"}
{"text": "Patients requiring or who were expected to require renal dialysis during the study were excluded .Patients with any previous intracranial hemorrhage , gastrointestinal bleeding within the past 6 months , or with known bleeding diathesis or coagulation disorder were excluded .", "label": "", "metadata": {}, "score": "95.75759"}
{"text": "Planned dental work up to and including Day 8 procedures .Treatment with another investigational drug , biological agent , or device within 4 weeks of Screening or 5 half - lives of the study agent , whichever is longer .", "label": "", "metadata": {}, "score": "96.02908"}
{"text": "Many events are early , at a time of coronary angiography , PCI , CABG , and other procedures , but the risk persists during later use of antiplatelet therapy .", "label": "", "metadata": {}, "score": "96.466"}
{"text": "Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "96.95973"}
{"text": "A small number of patients with a history of stroke were included .Based on information external to PEGASUS , 102 patients with a history of stroke ( 90 of whom received study drug ) were terminated early and no further such patients were enrolled .", "label": "", "metadata": {}, "score": "97.07858"}
{"text": "Clinically significant abnormal findings on the physical examination , ECG , blood pressure , heart rate , medical history , or clinical laboratory results at Screening or before dosing .", "label": "", "metadata": {}, "score": "97.205444"}
{"text": "Allocation : Randomized Endpoint Classification : Pharmacokinetics Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "97.40293"}
{"text": "Blood donation ( 1 unit or more ) within 1 month prior to study treatment or plasma donation within 7 days prior to study treatment .", "label": "", "metadata": {}, "score": "97.49363"}
{"text": "Inclusion Criteria : .Body Mass Index ( BMI ) between 18 and 27 kg / m^2 , inclusive .Exclusion Criteria : .Clinically relevant abnormalities of physical examination , laboratory values , vital signs or ECG findings at the screening , as judged by the Investigator or Sub - Investigator .", "label": "", "metadata": {}, "score": "98.066505"}
{"text": "PLATO excluded patients at increased risk of bradycardic events ( e.g. , patients who have sick sinus syndrome , 2nd or 3rd degree AV block , or bradycardic - related syncope and not protected with a pacemaker ) .", "label": "", "metadata": {}, "score": "98.24523"}
{"text": "Inability to comply with study requirements .Vigorous exercise ( as determined by the Investigator ) within 72 hours prior to any study visit .Other unspecified reasons that , in the opinion of the Investigator or Biogen Idec , make the subject unsuitable for enrollment .", "label": "", "metadata": {}, "score": "98.83391"}
{"text": "Allocation : Randomized Endpoint Classification : Pharmacokinetics / Dynamics Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Basic Science .", "label": "", "metadata": {}, "score": "98.89088"}
{"text": "Positive blood screen for hepatitis C antibody , or HIV or hepatitis B antigen .Indicators of abnormal renal function at baseline : any urine protein .", "label": "", "metadata": {}, "score": "98.90792"}
{"text": "Unwillingness or inability to follow the procedures outlined in the protocol .Urinary cotinine levels indicative of smoking or history of regular use of tobacco- or nicotine - containing products prior to screening .", "label": "", "metadata": {}, "score": "99.06987"}
{"text": "Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 1 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator )", "label": "", "metadata": {}, "score": "99.54965"}
{"text": "Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 1 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )", "label": "", "metadata": {}, "score": "99.77838"}
{"text": "A history of breathing problems ( i.e. history of asthmatic symptomatology , unless asthma in childhood that has now resolved and no longer requires maintenance therapy which should not be an exclusion ) .", "label": "", "metadata": {}, "score": "99.84552"}
{"text": "Table 4 shows the study results for the primary composite endpoint and the contribution of each component to the primary endpoint .Separate secondary endpoint analyses are shown for the overall occurrence of CV death , MI , and stroke and overall mortality .", "label": "", "metadata": {}, "score": "99.89914"}
{"text": "Table 6 shows the study results for the primary composite endpoint and the contribution of each component to the primary endpoint .Separate secondary endpoint analyses are shown for the overall occurrence of CV death , MI , and stroke and overall mortality . 1 Dosed at 90 mg bid . 2 Note : rates of first events for the components CV Death , MI and Stroke are the actual rates for first events for each component and do not add up to the overall rate of events in the composite endpoint .", "label": "", "metadata": {}, "score": "100.27718"}
{"text": "Any clinically important abnormality identified at the screening medical assessment ( physical examination / medical history ) , clinical laboratory tests , or ECG ( 12-lead ) .", "label": "", "metadata": {}, "score": "100.54155"}
{"text": "Exclusion Criteria : .WOCBP .Women who are pregnant or breastfeeding .Women with a positive pregnancy test on enrollment or prior to administration of investigational product .", "label": "", "metadata": {}, "score": "101.00073"}
{"text": "WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert , MedlinePlus , Practice Guidelines , Scientific Statements , and scholarly medical literature .", "label": "", "metadata": {}, "score": "101.3977"}
{"text": "Exclusion Criteria : .Known to have a positive test result for Human Immunodeficiency Virus ( HIV ) antibody .Known history of hepatitis C or hepatitis B virus .", "label": "", "metadata": {}, "score": "101.72544"}
{"text": "Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography , percutaneous coronary intervention ( PCI ) , CABG , or other surgery .", "label": "", "metadata": {}, "score": "102.163376"}
{"text": "Large documents may take several minutes to open .November 12 , 2015 .GSK has concluded that it is not feasible to publish this study in a peer - reviewed scientific journal because the nature of the study is unlikely to be of interest to a journal .", "label": "", "metadata": {}, "score": "102.17249"}
{"text": "Allocation : Randomized Endpoint Classification : Safety Study Intervention Model : Crossover Assignment Masking : Double Blind ( Subject , Investigator )Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "102.307205"}
{"text": "Current or chronic history of liver disease , or known hepatic or biliary abnormalities ( with the exception of Gilbert 's syndrome ) .A positive test for HIV antibody .", "label": "", "metadata": {}, "score": "102.47912"}
{"text": "Any other sound medical , psychiatric and/or social reason as determined by the investigator .Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination , vital signs , ECG or clinical laboratory determinations .", "label": "", "metadata": {}, "score": "102.93483"}
{"text": "Major bleed - fatal / life - threatening .Major bleed - other .Any one of the following : significantly disabling ( e.g. , intraocular with permanent vision loss ) ; clinically overt or apparent bleeding associated with a decrease in Hb of 3 g / dL ; transfusion of 2 - 3 units ( whole blood or PRBCs ) for bleeding .", "label": "", "metadata": {}, "score": "103.07761"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00976144 Detail Information .Publications 15 .", "label": "", "metadata": {}, "score": "103.66191"}
{"text": "PEGASUS .The PEGASUS TIMI-54 study was a 21162-patient , randomized , double - blind , placebo - controlled , parallel - group study .", "label": "", "metadata": {}, "score": "105.230545"}
{"text": "The subject is capable of giving informed consent , which includes compliance with the requirements and restrictions listed in the consent form .Available to complete the study .", "label": "", "metadata": {}, "score": "106.28696"}
{"text": "PLATO patients were predominantly male ( 72 % ) and Caucasian ( 92 % ) .The study 's primary endpoint was the composite of first occurrence of cardiovascular death , non - fatal MI ( excluding silent MI ) , or non - fatal stroke .", "label": "", "metadata": {}, "score": "107.344086"}
{"text": "Exclusion Criteria : - Hepatitis B or Hepatitis C positive - Current or chronic history of liver disease , or known hepatic or biliary abnormalities ( with the exception of Gilbert 's syndrome or asymptomatic gallstones ) .", "label": "", "metadata": {}, "score": "108.24086"}
{"text": "Japanese ethnic origin defined as having been born in Japan with four ethnic Japanese grandparents and able to speak Japanese .Male or female between 20 and 65 years of age inclusive , at the time of signing the informed consent .", "label": "", "metadata": {}, "score": "108.44693"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "109.76429"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "112.25688"}
{"text": "History of any clinically important cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , and renal , or other major disease , as determined by the Investigator .", "label": "", "metadata": {}, "score": "112.733925"}
{"text": "The primary endpoint was the composite of first occurrence of CV death , non - fatal MI and non - fatal stroke .CV death and all - cause mortality were assessed as secondary endpoints .", "label": "", "metadata": {}, "score": "113.6393"}
{"text": "Men , ages 20 to 45 , and men and women [ not of childbearing potential ( i.e. , who are postmenopausal or surgically sterile ) ] , ages 65 or older .", "label": "", "metadata": {}, "score": "118.198105"}
{"text": "a For the components , the first - occurring component of the composite is included .b The number of first events for the components CV Death , MI and Stroke are the actual number of first events for each component and do not add up to the number of events in the composite endpoint .", "label": "", "metadata": {}, "score": "121.51288"}
{"text": "Enrollment ICMJE .Completion Date .March 2003 .Primary Completion Date .March 2003 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "123.432846"}
{"text": "Org \u00a9 2015 All Rights Researved Princeton , New Jersey 08540 , USA", "label": "", "metadata": {}, "score": "150.37834"}
